TY  - JOUR
AU  - Bittner, Vera A
AU  - Szarek, Michael
AU  - Aylward, Philip E
AU  - Bhatt, Deepak L
AU  - Diaz, Rafael
AU  - Edelberg, Jay M
AU  - Fras, Zlatko
AU  - Goodman, Shaun G
AU  - Halvorsen, Sigrun
AU  - Hanotin, Corinne
AU  - Harrington, Robert A
AU  - Jukema, J Wouter
AU  - Loizeau, Virginie
AU  - Moriarty, Patrick M
AU  - Moryusef, Angèle
AU  - Pordy, Robert
AU  - Roe, Matthew T
AU  - Sinnaeve, Peter
AU  - Tsimikas, Sotirios
AU  - Vogel, Robert
AU  - White, Harvey D
AU  - Zahger, Doron
AU  - Zeiher, Andreas M
AU  - Steg, Ph Gabriel
AU  - Schwartz, Gregory G
AU  - ODYSSEY OUTCOMES Committees and Investigators
PY  - 2020
DO  - 10.1016/j.jacc.2019.10.057
UR  - https://hdl.handle.net/10668/25088
T2  - Journal of the American College of Cardiology
AB  - Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). A pre-specified analysis of the...
LA  - en
KW  - acute coronary syndromes
KW  - alirocumab
KW  - low-density lipoprotein cholesterol
KW  - major adverse cardiovascular events
KW  - proprotein convertase subtilisin/kexin type 9 inhibition
KW  - Acute Coronary Syndrome
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - Cardiovascular Diseases
KW  - Cholesterol, LDL
KW  - Female
KW  - Humans
KW  - Lipoprotein(a)
KW  - Male
KW  - Middle Aged
KW  - Risk Factors
KW  - Treatment Outcome
TI  - Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
TY  - research article
VL  - 75
ER  -